Oncolytics Biotech Inc T.ONC

Roche's I/O TIGIT + Tecentriq combo effective .. BUT ...

[Noteable]

' New follow-up data for Roche’s Tecentriq-tiragolumab combination therapy in certain lung cancer patients have analysts sighing in relief that the anti-TIGIT element appears to be pulling its weight, but two deaths in the combination arm hit the company's shares Friday morning.'

Safety data weren't clean, however, as there were two grade 5 events—which in trial speak means deaths—specifically both from the combo arm of the trial. The two treatment-related deaths were the results of pyrexia—or fever—and infection, according to detailed data presented at the European Society for Medical Oncology Immuno-Oncology virtual congress. Shares were off nearly 1% in early premarket trading on this update, taking the shine off the data.

Roche is fighting with Merck—and, further back, Bristol Myers Squibb—to make TIGIT work big in cancer, with checkpoint inhibitor combos appearing to be the way to go for both pharmas.

https://www.fiercebiotech.com/biotech/roche-posts-impressive-tigit-combo-lung-cancer-data-as-jefferies-read-blockbuster-sales-tea

 

[Noteable]

Interim data from Genentech (Roche)'s first randomized study of a candidate treatment for extensive-stage small cell lung cancer (ES-SCLC) failed to meet its co-primary endpoint in an unfortunate loss in the battle against the hard-to-treat disease.  Key secondary endpoints were safety and OS and PFS in all participants. Tiragolumab is an immune checkpoint

[Noteable]

Safety data wasn't clean, as there were two grade 5 events—which in trial speak means deaths—from the combo arm of the trial according to detailed data presented at the European Society for Medical Oncology Immuno-Oncology virtual congress in December 2021. The two treatment-related deaths were the results of pyrexia—or fever—and infection.

[Noteable]

Unusually, Roche moved tiragolumab into a phase 3 clinical trial in patients with extensive-stage SCLC on the strength of the efficacy seen in another indication. Roche had no randomized controlled data in SCLC, but the effect of giving tiragolumab and a checkpoint inhibitor to patients with non-small cell lung cancer (NSCLC) persuaded it to take “a calculated risk” and add the indication to its

[Noteable]

https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?threadid=35345111

[Noteable]

https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-ord-shs?postid=35489298